Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 34Cyclophosphamide 34Peripheral Blood Stem Cell Transplantation 23Busulfan 22Mycophenolic Acid 21Cyclosporine 20Whole-Body Irradiation 19Tacrolimus 18Antilymphocyte Serum 18Melphalan 16Filgrastim 16Radiotherapy 15Methotrexate 14fludarabine 12Cord Blood Stem Cell Transplantation 12Methylprednisolone 10Cytarabine 10Etoposide 8sargramostim 6Granulocyte Colony-Stimulating Factor 5Cyclosporins 5Alemtuzumab 4thymoglobulin 3merphos 3Tretinoin 3Thiotepa 3Thalidomide 3Sirolimus 3Rituximab 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × romidepsin × Classical hematology × Clear all
NCT00042822 2011-05-17

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡